ENZ - Enzo Biochem, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
New York,
United States
Type: Equity
ENZ price evolution
ENZ
| (in millions $) | 1 Dec 2022 | 31 Aug 2022 | 30 May 2022 | 3 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21.6 | $31.13 | ||
| Short term investments | ||||
| Net receivables | $11.52 | $11.52 | $11.76 | $15.32 |
| Inventory | $15.79 | $15.41 | $14.93 | $13.85 |
| Total current assets | $44.58 | $54.35 | $62.3 | $66.71 |
| Long term investments | ||||
| Property, plant & equipment | $31.56 | $32.43 | $32.51 | $32.93 |
| Goodwill & intangible assets | $7.45 | $7.48 | ||
| Total noncurrent assets | $41.5 | $41.6 | ||
| Total investments | ||||
| Total assets | $85.2 | $95.86 | $103.9 | $108.82 |
| Current liabilities | ||||
| Accounts payable | $8.11 | $8.51 | $7.66 | $6.86 |
| Deferred revenue | ||||
| Short long term debt | $3.74 | $3.41 | ||
| Total current liabilities | $24.25 | $24.55 | $24.7 | $26.15 |
| Long term debt | $4 | $4.12 | $4.24 | $4.35 |
| Total noncurrent liabilities | $16.84 | $17.02 | ||
| Total debt | $20.59 | $20.42 | ||
| Total liabilities | $40.21 | $41.4 | $41.72 | $43.7 |
| Shareholders' equity | ||||
| Retained earnings | -$299.27 | -$288.64 | -$280.2 | -$275.35 |
| Other shareholder equity | $3.88 | $3.15 | $2.88 | $1.97 |
| Total shareholder equity | $54.46 | $62.19 | ||
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21.6 | $13.52 | $47.87 | $60.15 |
| Short term investments | $29.98 | |||
| Net receivables | $11.52 | $10.2 | $9.14 | $10.74 |
| Inventory | $15.41 | $12.65 | $7.78 | $7.84 |
| Total current assets | $54.35 | $70.58 | $68.77 | $81.45 |
| Long term investments | ||||
| Property, plant & equipment | $32.43 | $33.6 | $34.4 | $14.25 |
| Goodwill & intangible assets | $7.45 | $7.7 | $7.99 | $8.48 |
| Total noncurrent assets | $41.5 | $43.11 | $43.77 | $25.19 |
| Total investments | $29.98 | |||
| Total assets | $95.86 | $113.69 | $112.54 | $106.64 |
| Current liabilities | ||||
| Accounts payable | $8.51 | $8.12 | $8.5 | $7.26 |
| Deferred revenue | ||||
| Short long term debt | $3.74 | $3.65 | $11.46 | |
| Total current liabilities | $24.55 | $26.08 | $32.8 | $16.01 |
| Long term debt | $16.84 | $19.03 | $21.36 | $4.18 |
| Total noncurrent liabilities | $16.84 | $19.03 | $21.36 | $4.6 |
| Total debt | $20.59 | $22.68 | $32.82 | $4.18 |
| Total liabilities | $41.4 | $45.1 | $54.16 | $20.61 |
| Shareholders' equity | ||||
| Retained earnings | -$288.64 | -$270.38 | -$278.25 | -$249.73 |
| Other shareholder equity | $3.15 | $1.35 | $1.68 | $2.58 |
| Total shareholder equity | $54.46 | $68.59 | $58.38 | $86.03 |
| (in millions $) | 31 Aug 2022 | 30 May 2022 | 3 Mar 2022 | 1 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $20.28 | $26.22 | ||
| Cost of revenue | ||||
| Gross Profit | $4.34 | $10.17 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $12.13 | $12.58 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.34 | -$1 | ||
| Net income | ||||
| Net income | -$8.43 | -$4.85 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $107.07 | $117.73 | $76.02 | $81.17 |
| Cost of revenue | $65.1 | $64.15 | $52.25 | $57.92 |
| Gross Profit | $41.97 | $53.58 | $23.77 | $23.25 |
| Operating activities | ||||
| Research & development | $3.77 | $3.25 | $4.45 | $3.17 |
| Selling, general & administrative | $53.71 | $49.63 | $49.69 | $44.27 |
| Total operating expenses | $56.97 | $52.88 | $54.14 | $21.52 |
| Operating income | -$15.01 | $0.69 | -$30.37 | $1.73 |
| Income from continuing operations | ||||
| EBIT | -$18.42 | $7.87 | -$28.97 | $1.43 |
| Income tax expense | ||||
| Interest expense | -$0.16 | -$0.01 | -$0.45 | -$1.06 |
| Net income | ||||
| Net income | -$18.26 | $7.88 | -$28.52 | $2.49 |
| Income (for common shares) | -$18.26 | $7.88 | -$28.52 | $2.49 |
| (in millions $) | 31 Aug 2022 | 30 May 2022 | 3 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$2.65 | |||
| Operating activities | ||||
| Depreciation | $0.7 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.87 | |||
| Total cash flows from operations | -$0.63 | |||
| Investing activities | ||||
| Capital expenditures | -$1.21 | |||
| Investments | -$0.03 | |||
| Total cash flows from investing | $25.22 | $25.59 | -$2.3 | -$1.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.06 | |||
| Total cash flows from financing | -$0.24 | -$0.14 | -$0.11 | -$0.06 |
| Effect of exchange rate | -$0.06 | -$0.07 | -$0.03 | -$0.02 |
| Change in cash and equivalents | $8.33 | $17.86 | -$9.11 | -$1.95 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$18.26 | $7.88 | -$28.52 | $2.49 |
| Operating activities | ||||
| Depreciation | $2.83 | $2.65 | $2.78 | $3.04 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.34 | $1.64 | $1.77 | $1.79 |
| Total cash flows from operations | -$16.59 | $0.39 | -$17.18 | $4.81 |
| Investing activities | ||||
| Capital expenditures | -$3.47 | -$4.44 | -$2.17 | -$8.13 |
| Investments | $28.7 | -$30.06 | ||
| Total cash flows from investing | $25.22 | -$34.5 | -$2.17 | -$8.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.1 | $0.17 | |
| Net borrowings | -$0.27 | -$0.34 | $7 | $4.03 |
| Total cash flows from financing | -$0.24 | -$0.24 | $7 | $4.19 |
| Effect of exchange rate | -$0.06 | $0.01 | $0.07 | -$0.02 |
| Change in cash and equivalents | $8.33 | -$34.34 | -$12.28 | $0.85 |
News
Fundamentals
| Market cap | $105.72M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 48.72M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -18.25% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.76 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.84 |
| Quick ratio | 1.19 |